NPJ Vaccines最新文献_第2页

Preexisting IgG forms immune complexes and links local thermal reactogenicity with immunogenicity in influenza vaccination. 在流感疫苗接种中，预先存在的IgG形成免疫复合物并将局部热反应性与免疫原性联系起来。

IF 6.5 1区医学

NPJ Vaccines Pub Date : 2026-05-02 DOI: 10.1038/s41541-026-01477-x

Julia R Hirsiger, Silke Scarascia, Mike Recher, Glenn Bantug, Christoph T Berger

{"title":"Preexisting IgG forms immune complexes and links local thermal reactogenicity with immunogenicity in influenza vaccination.","authors":"Julia R Hirsiger, Silke Scarascia, Mike Recher, Glenn Bantug, Christoph T Berger","doi":"10.1038/s41541-026-01477-x","DOIUrl":"https://doi.org/10.1038/s41541-026-01477-x","url":null,"abstract":"Pre-existing pathogen-specific antibodies shape vaccine outcomes, yet their impact on local reactogenicity and qualitative features of the immune response are not fully defined. In this prospective human cohort receiving seasonal influenza vaccination, high baseline hemagglutinin-specific IgG1 levels were associated with more pronounced local thermal responses at the vaccinated arm and greater vaccine-induced antibody levels. These IgG antibodies formed immune complexes with hemagglutinin, activated complement and enhanced Fc-receptor-dependent monocyte activation and phagocytosis in vitro, connecting pre-existing immunity to innate activation and local reactogenicity. Despite higher antibody levels and early plasmablast responses in subjects with strong thermal reactogenicity after vaccination, we observed lower avidity and hemagglutinin-inhibition capacity, suggesting extrafollicular responses. T cell responses were unaltered. These findings support a model in which pre-existing hemagglutinin-specific IgG may contribute to local thermal reactogenicity and qualitative features of the vaccine response through immune complex-mediated pathways, providing a framework for how prior immunity may shape human vaccine responsiveness.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":6.5,"publicationDate":"2026-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147818487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lipid nanoparticle-encapsulated DNA vaccine prevented lung consolidation following heterologous influenza A virus challenge in pigs. 脂质纳米颗粒包裹DNA疫苗预防猪异源甲型流感病毒攻击后肺实变。

IF 6.5 1区医学

NPJ Vaccines Pub Date : 2026-05-02 DOI: 10.1038/s41541-026-01473-1

The N Nguyen, Danh C Lai, Hung Q Luong, Kassandra Durazo-Martínez, Sushmita Kumari, Sarah Sillman, Phillip Gauger, Giao P Trinh, Hiep L X Vu

{"title":"Lipid nanoparticle-encapsulated DNA vaccine prevented lung consolidation following heterologous influenza A virus challenge in pigs.","authors":"The N Nguyen, Danh C Lai, Hung Q Luong, Kassandra Durazo-Martínez, Sushmita Kumari, Sarah Sillman, Phillip Gauger, Giao P Trinh, Hiep L X Vu","doi":"10.1038/s41541-026-01473-1","DOIUrl":"https://doi.org/10.1038/s41541-026-01473-1","url":null,"abstract":"The substantial antigenic diversity of Influenza A virus (IAV) presents significant challenges to the development of broadly protective vaccines for swine. Moreover, pigs vaccinated with whole-inactivated virus or hemagglutinin (HA) subunit vaccines may experience more severe lung consolidation than non-vaccinated pigs when exposed to antigenically mismatched IAV strains, a phenomenon known as vaccine-associated enhanced respiratory disease (VAERD). We recently developed a lipid nanoparticle-encapsulated DNA (LNP-DNA) vaccine encoding the HA of IAV, which elicited robust immune responses following a single immunization and protected pigs against homologous IAV challenges. In this study, we compared the immunogenicity and protective efficacy between the HA protein-based vaccine and the HA DNA-based vaccine against an antigenically mismatched IAV strain in pigs. Neither vaccine induced cross-reactive hemagglutination inhibition (HI) antibodies nor prevented viral shedding in nasal secretions following heterologous challenge. However, while the HA protein-based vaccine exacerbated lung lesions compared to non-vaccinated controls, the HA DNA-based vaccine prevented the development of gross lung pathology. Transcriptomic analyses revealed distinct gene expression profiles between the two vaccine groups. These findings suggest that the LNP-DNA vaccine platform may offer a safer and more effective strategy for developing vaccines against IAV in swine.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":6.5,"publicationDate":"2026-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147818485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High affinity is insufficient for strong B cell activation by HIV broadly neutralising antibodies. 高亲和力不足以使B细胞被HIV广泛中和抗体激活。

IF 6.5 1区医学

NPJ Vaccines Pub Date : 2026-05-02 DOI: 10.1038/s41541-026-01468-y

Chloe Rees-Spear, Olivia Payne, Emma Touizer, Alan Kennedy, Luke Muir, Peter Thomas, Alyssa Thomas DeCruz, Rachel A McKendry, Leo Swadling, Marit J van Gils, James E Voss, Laura E McCoy

{"title":"High affinity is insufficient for strong B cell activation by HIV broadly neutralising antibodies.","authors":"Chloe Rees-Spear, Olivia Payne, Emma Touizer, Alan Kennedy, Luke Muir, Peter Thomas, Alyssa Thomas DeCruz, Rachel A McKendry, Leo Swadling, Marit J van Gils, James E Voss, Laura E McCoy","doi":"10.1038/s41541-026-01468-y","DOIUrl":"https://doi.org/10.1038/s41541-026-01468-y","url":null,"abstract":"HIV broadly neutralizing antibodies (bnAbs) have been widely studied, and inducing a robust broadly neutralizing response remains a goal for many human vaccine studies. Much research focusses on creating higher affinity antigens to target bnAb precursors, however this ignores the role of non-neutralisers that are known to dominate HIV-specific responses. Furthermore, any effective vaccine will likely need to induce multiple bnAbs. Here, we question whether the previously postulated affinity ceiling of 10-9M limits bnAb induction above a certain affinity. Using adeno-associated virus (AAV)-mediated CRISPR-Cas9 engineering to express HIV-specific bnAbs and non-bNAbs in Ramos B cells, we investigate antigen-specific activation by BCRs of known binding/neutralization potency, epitope and affinity. We found that between different bnAb epitopes affinity was not predictive of activation. However, within individual epitopes and across non-bnAb epitopes, increased affinity results in increased activation. We propose that at activation-resistant bnAb epitopes, affinity is overruled to an extent by the physical BCR-antigen interaction, while more 'simple' and immunogenic non-bnAb epitopes are more heavily dependent on BCR affinity. These findings may have significant consequences for vaccine development, as a high affinity BCR-antigen interaction at an epitope with poor activation potential may be unsuccessful at participating in the humoral response.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":6.5,"publicationDate":"2026-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147818475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Superior protection against tuberculosis using heterologous mRNA nanoadjuvant vaccines. 异源mRNA纳米佐剂疫苗对结核病的卓越保护作用。

IF 6.5 1区医学

NPJ Vaccines Pub Date : 2026-05-02 DOI: 10.1038/s41541-026-01476-y

Bubacarr J B Touray, Alieu K Faburay, Fakry F Mohamed, Sherein S Abdelgayed, Adel M Talaat

{"title":"Superior protection against tuberculosis using heterologous mRNA nanoadjuvant vaccines.","authors":"Bubacarr J B Touray, Alieu K Faburay, Fakry F Mohamed, Sherein S Abdelgayed, Adel M Talaat","doi":"10.1038/s41541-026-01476-y","DOIUrl":"https://doi.org/10.1038/s41541-026-01476-y","url":null,"abstract":"Tuberculosis (TB) remains a major global health threat, underscoring the need for vaccines that surpass BCG efficacy. We developed QTAP-R, a novel mRNA-lipid nanoparticle (LNP) vaccine encoding Ag85B, Hsp70, and ESAT-6, to enhance immunity against Mycobacterium tuberculosis. QTAP efficiently encapsulated and delivered mRNA with high transfection efficiency and low cytotoxicity. In C57BL/6 mice, QTAP-R induced strong antigen-specific IgG and T-cell responses, including elevated CD4⁺ and CD8⁺ activation and increased polyfunctional cytokines (IFN-γ, TNF-α, IL-2, IL-17A). When combined with BCG (BCG + QTAP-R), the vaccine elicited enhanced immune memory, reduced bacterial burden in lungs and spleen, and minimized lung pathology following M. tuberculosis challenge. Subcutaneous QTAP-R (QTAP-SQ) provided partial protection under high-dose challenge, outperforming intranasal delivery. Transcriptomic profiling revealed upregulation of inflammatory cytokines (IL-1, IL-6, IL-12) and chemokines (CCL3, CCL4, CXCL9, CXCL10), indicating enhanced immune recruitment and activation. CD4⁺ T-cell depletion abolished protection, confirming their critical role in QTAP-R-mediated immunity. Overall, QTAP-R demonstrates potent immunogenicity and synergistic efficacy with BCG, positioning it as a promising mRNA-based TB vaccine candidate.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":6.5,"publicationDate":"2026-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147818501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quillaja saponaria fraction QS-18 as an adjuvant for liposomal seasonal influenza vaccines. 黄芪提取物QS-18作为季节性流感脂质体疫苗佐剂的研究。

IF 6.5 1区医学

NPJ Vaccines Pub Date : 2026-04-28 DOI: 10.1038/s41541-026-01457-1

Qinzhe Li, Zachary Sia, Yuan Luo, Wei-Chiao Huang, Hilliard L Kutscher, Haojun Zhu, Joaquin Ortega, Bruce A Davidson, Jonathan F Lovell

引用次数: 0

HER-2 therapeutic vaccine is not hampered by concurrent HER-2 monoclonal antibody. HER-2治疗性疫苗不受并发HER-2单克隆抗体的阻碍。

IF 6.5 1区医学

NPJ Vaccines Pub Date : 2026-04-27 DOI: 10.1038/s41541-026-01462-4

Maria Sofia Semprini, Chiara Cappello, Laura Scalambra, Olga Maria Pittino, Stefania Angelicola, Patrizia Nanni, Pier-Luigi Lollini, Francesca Ruzzi

{"title":"HER-2 therapeutic vaccine is not hampered by concurrent HER-2 monoclonal antibody.","authors":"Maria Sofia Semprini, Chiara Cappello, Laura Scalambra, Olga Maria Pittino, Stefania Angelicola, Patrizia Nanni, Pier-Luigi Lollini, Francesca Ruzzi","doi":"10.1038/s41541-026-01462-4","DOIUrl":"https://doi.org/10.1038/s41541-026-01462-4","url":null,"abstract":"ES2B-C001 represents a new generation of vaccines based on virus-like particles (VLP) that display the full extracellular domain of HER-2 and has now entered clinical development. ES2B-C001 elicited strong anti-HER-2 antibody responses that cured human HER-2 transgenic tumors and metastases in mice. Early vaccine trials may include patients who are still receiving anti-HER-2 monoclonal antibody (MAb) therapy, a clinical scenario that has not typically been addressed in preclinical studies. To evaluate whether the concurrent administration of 4D5 anti-HER-2 MAb affects the immunogenicity or the therapeutic efficacy of ES2B-C001, we administered concurrent treatments to tumor-free or to human HER-2 transgenic mammary carcinoma-bearing mice. In tumor-free mice, 4D5 treatment did not hamper either ES2B-C001 activity, which induced a strong anti-HER-2 IgG production, or T cell responses. In tumor-bearing mice, the therapeutic efficacy of ES2B-C001 was not compromised by 4D5, resulting in 13/20 long-term tumor-free mice with ES2B-C001 alone, versus 15/20 with the combined treatment. ES2B-C001 elicited robust HER-2-specific antibody responses, reaching concentrations in the milligram/mL range and persisting for >6 months post-treatments, regardless of prior 4D5 administration. These findings indicate that co-administration of an anti-HER-2 MAb does not impair the efficacy of ES2B-C001, supporting the feasibility of vaccinating patients undergoing trastuzumab therapy.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":6.5,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Protective immunity against malaria by a nanoparticle CIS43-based junctional vaccine alone or in combination with R21. 基于cis43的纳米颗粒连接疫苗单独或与R21联合对疟疾的保护性免疫。

IF 6.5 1区医学

NPJ Vaccines Pub Date : 2026-04-27 DOI: 10.1038/s41541-026-01455-3

Prabhanshu Tripathi, Ja-Hyun Koo, Xuejun Chen, Lais Da Silva Pereira, Marlon Dillon, Baoshan Zhang, Mariah Lofgren, Katelyn T Nguyen, I-Ting Teng, Brian Bonilla, Sarah Kerscher, Wing-Pui Kong, Amy R Henry, Tyler Stephens, Yaroslav Tsybovsky, Stephanie R Weldon, Daniel C Douek, Theodore C Pierson, Facundo D Batista, Azza H Idris, Robert A Seder, Peter D Kwong, Tongqing Zhou

{"title":"Protective immunity against malaria by a nanoparticle CIS43-based junctional vaccine alone or in combination with R21.","authors":"Prabhanshu Tripathi, Ja-Hyun Koo, Xuejun Chen, Lais Da Silva Pereira, Marlon Dillon, Baoshan Zhang, Mariah Lofgren, Katelyn T Nguyen, I-Ting Teng, Brian Bonilla, Sarah Kerscher, Wing-Pui Kong, Amy R Henry, Tyler Stephens, Yaroslav Tsybovsky, Stephanie R Weldon, Daniel C Douek, Theodore C Pierson, Facundo D Batista, Azza H Idris, Robert A Seder, Peter D Kwong, Tongqing Zhou","doi":"10.1038/s41541-026-01455-3","DOIUrl":"10.1038/s41541-026-01455-3","url":null,"abstract":"Repetitive display of the major repeats of the Plasmodium falciparum circumsporozoite protein (PfCSP) is the basis for two WHO-recommended vaccines: RTS,S/AS01 and R21/Matrix-M. Recently, however, the CIS43 monoclonal antibody that preferentially targets the junctional region of PfCSP has been shown to be highly protective in humans, highlighting its junctional epitope as a key vaccine target. Here, we develop a vaccine based on tandem repeats of the junctional epitope displayed on a self-assembling nanoparticle and compare this CIS43-based junctional vaccine alone or in combination with the benchmark R21 vaccine, using both B cell analysis and monoclonal antibody isolation to define targeting of the immune response. Comparable reduction in liver burden was observed following vaccination with the best junctional vaccine and R21 at a dose of 1 μg. At a dose of 0.25 μg, a modest reduction of malaria liver burden with the junctional vaccine was observed compared to R21. Further, combining the junctional and R21 vaccines did not yield substantial improvement, although a modest trend was observed. While the R21 vaccine elicited antibodies primarily against the major repeats, the junctional vaccine elicited antibodies against both junctional and major repeat regions. In vivo B cell analysis and isolation of monoclonal antibodies confirmed differences in vaccine-induced antibody specificities. Altogether, these data suggest the nanoparticle-formatted tandem-repeated CIS43-junctional vaccine to be a promising approach to broaden immunity against malaria, either as a standalone intervention or in combination with R21.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":6.5,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preclinical efficacy of dendritic cells loaded with newly identified HPV11 E6-derived CD8⁺ T cell epitopes. 树突状细胞装载新鉴定的HPV11 e6来源的CD8+ T细胞表位的临床前疗效。

IF 6.5 1区医学

NPJ Vaccines Pub Date : 2026-04-27 DOI: 10.1038/s41541-026-01466-0

Laurie Baert, Chao Gu, Agnes Yang, HyeMee Joo, Richard Kennedy, Kieth Knutson, David G Lott, SangKon Oh

{"title":"Preclinical efficacy of dendritic cells loaded with newly identified HPV11 E6-derived CD8+ T cell epitopes.","authors":"Laurie Baert, Chao Gu, Agnes Yang, HyeMee Joo, Richard Kennedy, Kieth Knutson, David G Lott, SangKon Oh","doi":"10.1038/s41541-026-01466-0","DOIUrl":"https://doi.org/10.1038/s41541-026-01466-0","url":null,"abstract":"Although the low-risk human papillomaviruses (HPVs), including HPV11, are mainly associated with low-grade lesions, they are also implicated in otolaryngologic malignancies and lung carcinomas. Nonetheless, T cell responses to the low-risk HPVs remain poorly understood. This study investigated HPV11 E6/7-specific T cell responses in C57BL/6 mice challenged with TC-1 tumor cells expressing HPV11 E6/7 proteins (TC-1.HPV11 E6/7). We identified two major CD8+ T cell epitopes, HPV11 E641-55 (AEIYAYAYKNLKVVW, p11) and E685-99 (YAPTVEEETNEDILK, p22). We next demonstrated that IFNα-matured bone marrow-derived dendritic cells (BMDCs) loaded with peptides p11 or p22 induced p11- and p22-specific CD8+ T cell responses, respectively. Furthermore, the administration of p11- or p22-loaded BMDCs matured with IFNα or BMDCs generated in the presence of p38 inhibitor/IL-15 and matured with TNFα, IL-1β, and prostaglandin E2, suppressed TC-1.HPV11.E6/7 tumor progression with increased infiltrations of p11- and p22-specific IFNγ+, TNFα+, and granzyme B+ CD8+ T cells in the tumors. In addition, BMDCs loaded with both peptide epitopes, p11 and p22, were more effective than BMDCs loaded with single epitopes in the suppression of TC-1.HPV11 E6/7 tumor progression. Data from this study will help with the rational design of therapeutic strategies for the diseases associated with HPV11 infection.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":6.5,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Influenza mRNA vaccine with engineered panhandle-forming UTRs provides potent, dose-sparing protection against seasonal influenza viruses. 具有工程化的长柄状utr的流感mRNA疫苗提供了有效的、剂量节约的季节性流感病毒保护。

IF 6.5 1区医学

NPJ Vaccines Pub Date : 2026-04-27 DOI: 10.1038/s41541-026-01463-3

Yifan Xu, Xuehua Wan, Mingzhuo Chen, Benchi Li, Qian Weng, Qin Wang, Zhiliang Hu, Yongxiang Yi, Junwei Li

{"title":"Influenza mRNA vaccine with engineered panhandle-forming UTRs provides potent, dose-sparing protection against seasonal influenza viruses.","authors":"Yifan Xu, Xuehua Wan, Mingzhuo Chen, Benchi Li, Qian Weng, Qin Wang, Zhiliang Hu, Yongxiang Yi, Junwei Li","doi":"10.1038/s41541-026-01463-3","DOIUrl":"https://doi.org/10.1038/s41541-026-01463-3","url":null,"abstract":"Influenza viruses pose a persistent threat to global public health, causing widespread respiratory illness and significant morbidity. Vaccination remains the most effective strategy to reduce the burden of both seasonal and pandemic influenza. mRNA vaccines represent a promising alternative to conventional vaccine platforms due to their rapid development, flexibility, and high efficacy. Nonetheless, optimizing non-coding regulatory elements such as untranslated regions (UTRs) remains crucial for enhancing mRNA vaccine performance. In this study, we designed a novel UTR derived from the influenza A virus M segment, engineered to form optimal panhandle structures through selective base-pair enhancing mutations (M1 + 2), aiming to improve mRNA translation efficiency and immunogenicity. Using both reporter and HA antigen-encoding mRNAs, we demonstrated that the M1 + 2 UTR significantly enhanced protein expression in vitro and in vivo compared to unmodified UTRs and the canonical α-globin UTR control. In a murine model, low-dose (0.1 μg) vaccination with HA mRNA-lipid nanoparticles (LNPs) incorporating the M1 + 2 UTR elicited robust innate, humoral, and T cell-mediated immune responses, and conferred complete protection against lethal challenge with seasonal influenza strains, including H1N1, H3N2, and IBV. Our findings underscore the potential of rational UTR design in developing more efficacious and dose-sparing mRNA vaccines.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":6.5,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An open repository of COVID-19 vaccine mandate studies with a worked scoping review of quasi-experimental evidence. 开放的COVID-19疫苗授权研究库，并对准实验证据进行工作范围审查。

IF 6.5 1区医学

NPJ Vaccines Pub Date : 2026-04-25 DOI: 10.1038/s41541-026-01454-4

Fabio I Martinenghi, Tanka Prashad Ojha, Amy Thomasson, Bianca Devsam, Shevaun Drislane, Sophie Vasiliadis, Chiara Berardi, Aregawi Gebremariam, Alessia Dipalma, Teresa Gavaruzzi, Jeremy K Ward, Francesco Paolucci, Margie Danchin, Mesfin Genie, Katie Attwell, Christopher C Blyth

{"title":"An open repository of COVID-19 vaccine mandate studies with a worked scoping review of quasi-experimental evidence.","authors":"Fabio I Martinenghi, Tanka Prashad Ojha, Amy Thomasson, Bianca Devsam, Shevaun Drislane, Sophie Vasiliadis, Chiara Berardi, Aregawi Gebremariam, Alessia Dipalma, Teresa Gavaruzzi, Jeremy K Ward, Francesco Paolucci, Margie Danchin, Mesfin Genie, Katie Attwell, Christopher C Blyth","doi":"10.1038/s41541-026-01454-4","DOIUrl":"https://doi.org/10.1038/s41541-026-01454-4","url":null,"abstract":"Vaccine mandates were widely implemented against COVID-19, and a large and multidisciplinary literature has emerged as a result, covering fields such as epidemiology, economics, ethics, and law. We compiled an openly available repository of this literature, including 503 studies on COVID-19 vaccine mandates. We identified them through a manual multi-database search and performed the data extraction using a large language model. The dataset stores information, for each study, on the scope and sanctions of the relevant mandate(s), the study design, target population, outcomes, and themes, allowing users to quickly navigate this complex literature. We use the dataset to present key statistical facts and insights about this literature, and we leave to other scholars the opportunity of interrogating it further. As a worked example, we conduct a narrative review of quasi-experimental studies on COVID-19 vaccine mandates. These consistently show short-run increases in first-dose uptake following mandate announcements, with limited evidence on long-run uptake and downstream social, health, and economic outcomes. We provide all data and code to support secondary analyses and future evidence syntheses.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":6.5,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0